Overcoming the emergence of acquired resistance to clinically approved epidermal growth factor receptor (EGFR) inhibitors is a major challenge in the treatment of advanced non-small cell lung cancer (NSCLC). The aim of this study was to investigate the effects of a series of novel compounds affecting viability of NSCLC NCI-H1975 cells (carrying the EGFR T790M mutation). The inhibition of the autophosphorylation of EGFR occurred at nanomolar concentrations and both UPR1282 and UPR1268 caused a significant induction of apoptosis. Targeting of EGFR and downstream pathways was confirmed by a peptide substrate array, which highlighted the inhibition of other kinases involved in NSCLC cell aggressive behavior. Accordingly, the drugs inhibited migration (about 30% vs. control), which could be, in part, explained also by the increase of E-cadherin expression. Additionally, we observed a contraction of the volume of H1975 spheroids, associated with the reduction of the cancer stem-like cell hallmark CD133. The activity of UPR1282 was retained in H1975 xenograft models where it determined tumor shrinkage (P < .05) and resulted well tolerated compared to canertinib. Of note, the kinase activity profile of UPR1282 on xenograft tumor tissues showed overlapping results with respect to the activity in H1975 cells, unraveling the inhibition of kinases involved in pivotal proliferation and invasive signaling pathways. In conclusion, UPR1282 and UPR1268 are effective against various processes involved in malignancy transformation and progression and may be promising compounds for the future treatment of gefitinib-resistant NSCLCs. Neoplasia (2013) 15, 61-72 
Introduction Non-small cell lung cancer (NSCLC) represents the majority of human epithelial cancers [1] . About 10% of NSCLCs is marked by functional activation of crucial "driver" oncoproteins with a pivotal dependency on growth factors and their receptors [2] . The epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptor tyrosine kinases. These receptors are commonly expressed in different tissues of epithelial, mesenchymal, and neural origins and their pivotal role in normal individual development has been largely investigated. The involvement of EGFR in the regulation of important tumorigenic processes, such as proliferation, apoptosis, angiogenesis, and invasion, has also been demonstrated for different tumor types [3] . Furthermore, activated ErbB receptors stimulate several intracellular signaling pathways including the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin and the Ras/Raf/mitogenactivated protein kinase pathways that have been demonstrated to play a key role in the control of numerous fundamental cellular processes. Along with its ligands (e.g., EGF, transforming growth factor-α, neuregulins), EGFR is often overexpressed and negatively correlated with prognosis in various tumor types, including NSCLC. In particular, the EGFR overexpression has been observed in 40% to 80% of NSCLC cases and multiple mutations of such receptor have been described and correlated with malignancy "oncogene addiction" [3] . Taken together, these findings identified EGFR as an ideal target for cancer therapy [4] . Small-molecule EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have been approved as first-line treatment in selected NSCLC patients, as well as second/third-line treatment or maintenance therapy in unselected patients [3] . The clinical response to TKIs is correlated with activating EGFR mutations, predominantly the common in-frame deletions of exon 19 (delE746-A750) and the missense point mutation L858R. These aberrations are currently used as biomarkers to select patients more likely to benefit from EGFR TKIs as first-line treatment [5] . Unfortunately, after a progression-free period of about 10 months, most of the patients responsive to EGFR TKIs inevitably relapse. The acquired resistance to first-generation EGFR TKIs can be caused by multiple mechanisms, including the secondary EGFR point mutation T790M that accounts for ∼50% of the cases [6, 7] . The amplification of the receptor for the hepatocyte growth factor (c-Met) was also described as important mechanism of acquired resistance to gefitinib or erlotinib being observed in 20% of the cases [8] . The coexistence of the T790M mutation with c-Met amplification was rarely described [9] .
A covalent interaction between EGFR TKIs with a cysteine residue located at the entrance of the EGFR adenosine triphosphate-binding cleft (Cys 797 ) was described as a possible mechanism to bypass the T790M-related resistance to gefitinib. Several second-generation irreversible inhibitors have been developed [10] [11] [12] [13] , and many compounds, such as canertinib [14] , afatinib [15] , neratinib [16] , and dacomitinib [17] , progressed to clinical investigation, with mixed results. Therefore, acquired resistance against first-line EGFR inhibitors so far remains one of the major challenges for NSCLC treatment and the identification of new molecules targeting EGFR T790M mutants is warranted.
Furthermore, other factors might lay the foundation of drug resistance and novel compounds should be evaluated for their abilities to overcome also these emerging mechanisms. Recent studies reported the epithelial-to-mesenchymal transition (EMT) as a pivotal mechanism involved in the resistance of cancer cells against conventional therapeutics [18, 19] . The EMT process results from a number of dramatic cellular and molecular changes, including dissolution of adherent junctions, reorganization of the cytoskeleton, loss of cell polarity, induction of pro-mesenchymal gene expression, and migration through basement membranes and tissues. Several studies reported the reduction of the expression of the epithelial cell junction protein E-cadherin as key biomarker of EMT in the development of resistance to EGFR inhibition in lung cancer [20] . Importantly, the EMT is also involved in the acquisition of tumor stem-like cell phenotype characterized by high potential of self-renewal in vitro and tumorigenicity in vivo [21] .
We recently developed a new series of irreversible EGFR inhibitors containing a 3-aminopropanamide fragment. The cytotoxicity of these compounds was previously tested in vitro in NSCLC H1975 cells [22] . Importantly, these molecules inhibited cell growth at considerably lower concentrations than gefitinib, showing irreversible inhibition of EGFR autophosphorylation, in spite of the lack of a cysteine-trapping warhead [22] . These compounds, while chemically stable in the extracellular environment, proved to be able to release an acrylamide derivative by retro-Michael degradation of the 3-aminopropanamide fragment in the intracellular environment. In principle, replacing the reactive acrylamide group of typical second-generation EGFR inhibitors by a chemically stable and basic aminopropanamide should confer both pharmaceutical (increased stability, water solubility, and bioavailability) and therapeutic (lower propensity to give nonspecific adducts with biological tissues) advantages. However, the ability of these procovalent inhibitors to exert antiproliferative activity on tumor cells can depend on the specific intracellular environment and must therefore be thoroughly examined. In particular, we investigated the activity of the 4-(3-chloro-4-fluoroanilino)-7-ethoxyquinazolino derivative UPR1282 and the 4-anilinoquinoline-3-carbonitrile derivative UPR1268 ( Figure 1A ) in both in vitro and in vivo models derived from the established gefitinibresistant NSCLC H1975 cell line, which harbors the EGFR T790M mutation. Other pancreatic and lung cancer cell lines were included in this investigation to compare and understand their effects in diseases where EGFR inhibitors have demonstrated to be active.
Materials and Methods

Drugs and Chemicals
The synthesis of UPR1282 and UPR1268 has previously been described by Carmi et al. [22] . Gefitinib was a generous gift from AstraZeneca (Macclesfield, United Kingdom). The drugs were dissolved in DMSO at the stock concentration of 10 mM and then diluted for the experiments in culture medium before use. RPMI medium, FBS, penicillin (50 IU/ml), and streptomycin (50 μg/ml) were from Gibco (Gaithersburg, MD). All other chemicals were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands).
Cell Culture
The human NSCLC cell lines NCI-H1975 (H1975), Calu-1, and A549 and the pancreatic ductal adenocarcinoma (PDAC) cell lines PANC-1 and MIA PaCa-2 were purchased from ATCC (Manassas, VA) and cultured as recommended. Cells were maintained as monolayers in RPMI 1640 (containing 2 mM L-glutamine) supplemented with 10% heat-inactivated FBS and 1% streptomycin and penicillin in a 37°C water-saturated atmosphere of 5% CO 2 in air in 75-cm 2 tissue culture flasks (Costar, Cambridge, MA). The cell lines were tested for their authentication by polymerase chain reaction (PCR) profiling using short tandem repeats, which was performed by BaseClear (Leiden, The Netherlands) in August 2011.
Cell Growth Inhibition
Cell growth inhibition was assessed by sulforhodamine B assay according to the National Cancer Institute (NCI) protocol with slight modifications [23] . The pure compounds were initially dissolved in DMSO and tested in triplicates in the range of 0.01 to 20 μM. The treatment was started on day 1 after plating, and cells were exposed to drugs for 72 hours. The control wells were exposed to 0.1% DMSO. After 72-hour treatment, 25 μl of ice-cold 50% (wt/vol) trichloroacetic acid were added to each well for 60 minutes at 4°C. Then, the sulforhodamine B assay was performed, as described previously [24] . The optical density (OD) of each well was measured at 540 nm by TiterTek Multiskan MCC/340 (Flow Laboratories, Inc, Rockville, MD) 96-well plate reader. Values were corrected for background OD from wells containing medium only supplemented with 0.1% DMSO. The inhibition of cell viability was calculated with respect to control DMSO-treated cells based on the difference in OD at the beginning (day 0) and after 72 hours of treatment (day 3), according to the NCI protocol [23] . The 50% growth inhibitory concentration (IC 50 ) was expressed as the concentration inhibiting 50% of the growth of drug-treated cells relative to the DMSO-only-treated ones and calculated by nonlinear least squares curve fitting (GraphPad Prism, Intuitive Software for Science, San Diego, CA). Microscopic images of H1975 cells exposed to 0.1% DMSO or UPR1282 and UPR1268 at their IC 50 s were taken immediately before (time zero) and after 72 hours of treatment by Leica DFC345 FX microscope (Leica Microsystems GmbH, Wetzlar, Germany; Figure W1 ).
Analysis of Apoptosis with Annexin V Staining and Mitochondrial Membrane Potential
For the Annexin V staining, H1975 cells were plated at a density of 2 × 10 5 cells/well in six-well plates. After 24 hours, 1 μM gefitinib or UPR1282 and UPR1268 at their respective IC 50 s were added and cells were then incubated for 24 hours. DMSO (0.1%) was added to the control wells. Cells were then trypsinized, harvested, transferred to test tubes (12 × 75 mm), and centrifuged at 1200 rpm for 10 minutes. The pellets were resuspended in 100 μl of ice-cold binding buffer (0.1 M Hepes/NaOH (pH 7.4), 1.4 M NaCl, and 25 μM CaCl 2 ). Annexin staining was performed according to the manufacturer's protocol (Annexin V-Fluorescein Isothiocyanate (FITC) Apoptosis Detection Kit I; Becton Dickinson, San Jose, CA), with minor modifications as previously described [25] . Cells were stained with both 5 μl of Annexin V-FITC and 5 μl of propidium iodide (PI) and incubated for 15 minutes at room temperature in the dark before adding 400 μl of binding buffer to each tube. Samples were then analyzed by flow cytometry in FACSCalibur Flow Cytometer (Becton Dickinson) and the results were processed using FACSDiva 6.0 software (Becton Dickinson). A total of 10,000 events were collected using excitation/emission wavelengths of 488/525 and 488/675 nm for Annexin V and PI, respectively.
For the analysis of the mitochondrial membrane potential, H1975 cells treated as described above were harvested and transferred to flow cytometer's tubes and incubated in phosphate-buffered saline (PBS) supplemented with 40 nM DiOC 6 (Sigma) for 20 minutes at 37°C in the dark. Then, cells were washed with PBS and the samples were analyzed with the FACSCalibur Flow Cytometer and the FACSDiva 6.0 software. A total of 10,000 events were acquired and living cells were defined by size [forward scatter (FSC)] and granularity [side scatter (SSC)].
Genetic Characterization of Cancer Cells
DNA was isolated from 10 6 cells per cell line, using the MiniDNA Kit (Qiagen, Hilden, Germany). DNA yields and purity were checked at 260 to 280 nm with NanoDrop 1000 Detector (NanoDrop Technologies, Wilmington, DE). Nested PCR to amplify EGFR (exons 18-21) and K-Ras (exons 1-2) and sequencing of PCR products on an ABI 3100 genetic analyzer (Applied Biosystems, Foster City, CA) were performed as described previously [24] . The AKT1-SNP4 G/A (dbSNP-ID:rs1130233) polymorphism was studied using a Taqman probe-based assay with specific primers and probes obtained from Applied Biosystems (C_7489835_10). PCRs were performed using 20 ng of DNA diluted in 5.94 μl of DNAse-RNAse-free water, with 6.25 μl of TaqMan Universal PCR Master Mix and 0.31 μl of the mix, including the primers and probes, in a total volume of 12.5 μl. After thermal cycling, the 7500HT instrument determined the allelic content of each sample in the plate by reading the generated fluorescence, using the SDS 2.0 software.
Quantitative Real-Time Reverse Transcription-PCR
Total RNA was isolated using the TRI Reagent LS (Invitrogen, Carlsbad, CA). One microgram of RNA was retro-transcribed using the DyNAmo cDNA Synthesis Kit (Thermo Scientific, Vantaa, Finland), according to the manufacturer's instructions. Primers and probes to specifically amplify CD133 and E-cadherin were obtained from Applied Biosystems Assay-on-Demand Gene expression products (Hs00901885_m1, Hs01023894_m1). The quantitative real-time PCR was performed in a 25-μl reaction volume containing TaqMan Universal Master Mix (Applied Biosystems). All reactions were performed in triplicate using the ABI Prism 7500 sequence detection system instrument (Applied Biosystems). Samples were amplified using the following thermal profile: 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of denaturation at 95°C for 15 seconds followed by annealing and extension at 60°C for 1 minute. A validation experiment was performed to demonstrate that the efficiencies of the targets (E-cadherin and CD133) and reference (β-actin) gene amplifications were approximately equal, using a standard curve method with several dilutions of the cDNA sample from untreated control H1975 cells. An ideal slope should be −3.32; the values of the slopes of cDNA calibrator relative to threshold cycle (C T ) for the target genes revealed PCR efficiencies above 95%. Amplifications were normalized to β-actin (TaqMan β-Actin Detection Reagents, Part No. 401846). The fold change was calculated by the ΔΔC T method and results were plotted as 2 −ΔΔCT .
Western Blot
After 1 hour of exposure to 0.1% DMSO or different concentrations of gefitinib (0.01 to 10 μM) and UPR1282 and UPR1268 (both from 0.001 to 10 μM), H1975 cells were stimulated for 5 minutes with EGF (50 μg/ml) and then lysed by RIPA buffer supplemented with protease and phosphatase inhibitor cocktails. Procedures for protein extraction, solubilization, and protein analysis by one-dimensional polyacrylamide gel electrophoresis (PAGE) are described elsewhere [26] . Samples of 40 to 50 μg of proteins were resolved by 10% sodium dodecyl sulfate-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. The following antibodies were used (Bioké, Leiden, The 1:1000), and monoclonal anti-p44/42 (1:1000). As secondary antibodies, goat anti-mouse InfraRedDye (1:10,000, 800CW; #926-32210 and 680CW; #926-32220; Westburg, Leusden, The Netherlands) or goat anti-rabbit InfraRedDye (1:10,000, 800CW; #926-32211 and 680CW; #926-32221) were used. As a loading control, expression of β-actin was determined using an antibody against β-actin in stripped membranes (1:10,000; Millipore Bioscience Research Agents, Temecula, CA). Fluorescent proteins were detected by an Odyssey Infrared Imager (LI-COR Biosciences, Lincoln, NE), at 84-μm resolution, 0-mm offset, using high-quality settings.
Peptide Substrate Array
To evaluate modulation of kinase activity by gefitinib, canertinib, and UPR1282 in H1975 cells and tissues from xenograft models, we profiled lysates from the cells and the tumors by using a kinase peptide substrate array (PamChip; PamGene International, 's-Hertogenbosch, The Netherlands) as previously described [27] . This array contains 144 peptides consisting of 15 amino acids including a tyrosine, usually in the middle of the peptide. The 13 COOH-terminal amino acids of each peptide correspond to known or putative phosphorylation sites in a variety of human proteins. The samples were lysed for 20 minutes at 4°C by M-PER containing phosphatase and protease inhibitors (Thermo Scientific, Rockford, IL). Lysates were centrifuged for 15 minutes at 10,000g; the supernatant was collected and stored at −80°C. Forty microliters of control sample mix for the kinase activity array was subsequently prepared by using reaction buffer containing 1× ABL buffer (Westburg), 100 μM adenosine triphosphate (Sigma-Aldrich), fluorescein-labeled antibody PY20 (Exalpha, Maynard, MA), 5 μg of (lysate) protein, and DMSO. Kinase inhibition was measured by the addition of 25 μM gefitinib, 25 μM canertinib, or 25 μM UPR1282 (final drug concentrations; DMSO concentration in all samples, 2.5%). After blocking the arrays with 2% BSA and subsequent loading of the sample mix onto the arrays, incubation (at 30°C) was started for 60 cycles using a PamStation 12 instrument. Repeated fluorescent imaging of each array was performed with a 12-bit charge-coupled device (CCD) camera, monitoring fluorescence intensities in real time. Spot intensity at each time point was quantified (and corrected for local background), and the resulting time-resolved curves were fit to calculate the initial phosphorylation rate (V ini ) using specific kinetic algorithms and appropriate statistical methods, by Bionavigator software version 5.1 (PamGene International).
In Vitro Migration Assay (Wound-Healing Assay)
Migration was evaluated using the LeicaDMI300B migration station (Leica Microsystems) integrated with the Scratch Assay 6.1 software (Digital Cell Imaging Labs, Keerbergen, Belgium). Thirty thousand H1975 cells per well were plated onto 96-well plates, and after 24 hours, artificial wound tracks were created by scraping with a specific scratcher within the confluent monolayers. After removal of the detached cells by gently washing with PBS, the medium was replaced and the cells were exposed to 0.1% DMSO, 1 μM gefitinib, or UPR1282 and UPR1268 at their respective IC 50 s. The ability of the cells to migrate into the wound area was assessed by comparing the pixels of the wound tracks in the images taken at the beginning of the exposure (time zero) with those taken after 4, 6, 8, and 24 hours [28] .
Activity on H1975-Derived Tumor Spheres
A subpopulation of lung cancer stem-like cells were isolated by culturing 1.5 × 10 4 H1975 cells per well in serum-free insulintransferrin-selenium (1:1000; Gibco, Invitrogen) supplemented with Dulbecco's modified Eagle's medium/F12 + GlutaMAX-I (1:1), in 24-well ultralow adherent plates (Corning Incorporated, Corning, NY), according to the manufacturers' protocol, as previously described [28] . The spheroids were generated for 20 to 25 days and then harvested for the growth inhibition studies in 96-well plates, as well as for RNA isolation. After checking their growth and stability, H1975 spheroids were treated with 0.1% DMSO, 1 μM gefitinib, as well as UPR1282 or UPR1268 at their IC 50 s. Each well was scanned at 0, 24, 48, and 72 hours of treatment. The effects of the drugs were evaluated in term of changes in the volume and in the total number of spheroids using the inverted phase contrast microscope LeicaDMI300B integrated with the Universal Grab 6. 
Tumor Xenografts
All experiments involving animals were performed in accordance with Guiding Principles in the Care and Use of Animals (DL116/92). Twenty-four BALB/c-Nude female mice (Charles River Laboratories, Calco, Italy) were housed in a protected unit for immunodeficient animals with 12-hour light/dark cycles and provided with sterilized food and water ad libitum. At the time of xenograft experiments, mice were 7 weeks old and weighted about 20 g. Two hundred microliters of matrigel (BD Biosciences, Franklin Lakes, NJ) and sterile PBS (1:1) containing 1 × 10 7 H1975 cells were subcutaneously injected on the right flank of each mouse (using a 1-ml syringe, needle G25). The injected cells generated a solid tumor localized in correspondence of injection site. When tumor volume reached an average size of 150 to 200 mm 3 , 1 month after injection, animals were randomized into four groups and treated for 25 days. At the end of the treatment, mice were killed by cervical dislocation and tumors were collected and stored at −80°C until used for peptide kinase array or formalin fixed for hematoxylin-eosin staining or immunohistochemistry.
Treatment and Tumor Measurement
Gefitinib, canertinib, and UPR1282 were orally administered, 5 days/week, at the dosage of 25 mg/kg in 1% Tween 80, while the animals in the control group received oral gavage of vehicle alone.
Tumor xenografts were measured twice a week and tumor volume was calculated using the formula: (length × width 2 )/2. Final data are expressed as percentage of volume increase: tumor volume/pretreatment tumor volume × 100.
Sections of formalin-fixed, paraffin-embedded xenograft tumors were stained with hematoxylin and eosin for initial histopathologic examination to confirm the presence of NSCLC cells. This is a widely used, two-stage stain for cells in which hematoxylin is followed by a counterstain of red eosin so that the nuclei stain a deep blue-black and the cytoplasm stains pink. This staining allows the detection of focally multinucleated cells and mitotic figures within the tumors.
Immunohistochemistry
Tumor tissue sections were constructed using tissue biopsies obtained from three mice from the different groups included in recipient paraffin blocks. Before staining with the monoclonal antibody from the EGFR pharmDx Kit, the slides were deparaffinized using xylene and rehydrated in alcohol, as described previously [29] . Negative controls were obtained by replacement of primary antibody with buffer (1× PBS). EGFR staining results were evaluated using a four-tier system including the analysis of both the number of positive cells and the staining intensity. All slides were reviewed by two independent observers who also evaluated the amount of tissue loss, background staining, and overall interpretability before the formal EGFR reactivity evaluation. Neoplastic cells were always uniformly stained, and positivity assessment was made by counting at least 2000 tumor representative cells.
Statistical Analysis
All experiments were performed in triplicate and repeated at least twice. Data were expressed as mean values ± SD and analyzed using the two-tailed Student's t test or analysis of variance followed by the Bonferroni's multiple comparison test, using Prism 5.0 (GraphPad Software). The level of significance was set at P < .05.
Results
Antiproliferative and Cytotoxic Effects
The novel UPR1282 and UPR1268 compounds ( Figure 1A) were evaluated in comparison to the first-generation EGFR TKI gefitinib for their ability to inhibit the growth and viability of different cell lines, including the gefitinib-resistant H1975 cell line harboring the T790M mutation ( Table 1 ). The 4-(3-chloro-4-fluoroanilino)-7-ethoxyquinazolino derivative UPR1282 was significantly more active in comparison with gefitinib in the three tested NSCLC cell lines. In particular, UPR1282 was nine-fold more effective than gefitinib in inhibiting H1975 proliferation but only two-fold in the NSCLC cell lines A549 and Calu-1. Because of the approval of the
EGFR TKI erlotinib in combination with gemcitabine [30] , for the treatment of advanced PDAC, we also evaluated the biological activity of our compounds in PDAC cells. Our molecules were as active as gefitinib in inhibiting the proliferation of both PANC-1 and MIA PaCa-2 cells. Moreover, a 16-fold difference compared to gefitinib was observed with UPR1268 in H1975 cells. This compound was also nine-and two-fold more effective than gefitinib in reducing A549 and Calu-1 cell viability, respectively. Furthermore, in the PDAC cells MIA PaCa-2, the same compound showed a five-to six-fold increase in potency with respect to the first-generation EGFR TKI. The inhibition of H1975 cell proliferation was detected also microscopically after exposure of the cells to UPR1282 and UPR1268 at their IC 50 s ( Figure W1 ). Apoptosis was investigated as potential mechanism of cell death induced by these compounds using cytofluorometric analysis of Annexin V staining and mitochondrial membrane potential. One micromolar gefitinib was chosen as treatment of reference, as it is the concentration more commonly used in the preclinical setting to reflect the mean blood concentration reached in NSCLC patients treated with the inhibitor. In apoptotic cells, the membrane phospholipid phosphatidylserine is translocated from the inner to the outer leaflet of the plasma membrane, thereby exposing phosphatidylserine to the external cellular environment. Annexin V labeled with the FITC fluorescent tag was used with flow cytometry to measure this event. Moreover, because Annexin V staining precedes the loss of membrane integrity that accompanies the later stages of cell death resulting from either apoptotic or necrotic processes, we used the staining with Annexin V-FITC in conjunction with a live/dead dye such as PI to allow the identification of early apoptotic cells (PI negative, Annexin V-FITC positive) from late apoptotic/dead cells (PI positive, Annexin V-FITC positive). The 24-hour treatment with the novel molecules increased both events, as illustrated in Figure 1B . In particular, IC 50 s of UPR1282 and UPR1268 increased the early apoptosis from 3.9 to 16.0 and 10.8% and the late apoptosis from 4.4 to 9.6 and 12.2%, respectively. Mitochondrial damage was assessed biochemically by measuring DiOC 6 , a cationic dye that is released when the mitochondrial membrane potential is damaged. As shown by the representative histograms of cytofluorometric analysis in Figure 1C , a clear decrease in the binding of DiOC 6 was observed in H1975 cells treated for 24 hours with UPR1282 and UPR1268, as described above. Conversely, no differences were observed in cells treated with gefitinib compared to control cells that were exposed to 0.1% DMSO (Figure 1 , B and C).
Inhibition of EGFR Autophosphorylation and Downstream Signaling Pathways
To get further insights into the mechanism of action of the new compounds compared to gefitinib, we investigated their effect on Figure 2 . EGFR and downstream pathway phosphorylation analyses by Western blot; 1 × 10 6 H1975 cells per well were plated in sixwell plates and, after 24 hours, were exposed for 1 hour to 0.01 to 10 μM gefitinib, 0.001 to 10 μM of both UPR1282 and UPR1268, or 0.1% DMSO (control). Stimulation with EGF (50 μg/ml) for 5 minutes was performed before protein extraction. Samples of 40 to 50 μg of proteins were resolved by 10% sodium dodecyl sulfate-PAGE and transferred to PVDF membranes. Fluorescent proteins were detected and analyzed by Odyssey Infrared Imager at 84-μm resolution, 0-mm offset, using high-quality settings. The immunoblot of gefitinib activity in H1975 cells has been previously published by Carmi et al. [10] .
crucial phosphorylation pathways (Figure 2) . A concentrationdependent inhibition of EGFR autophosphorylation in H1975 cells was observed after exposure to both UPR1282 and UPR1268, with IC 50 of 0.08 and 0.15 μM, respectively. A complete inhibition of EGFR phosphorylation was reached by both UPR compounds at the highest tested concentration (10 μM). In the same experimental conditions, gefitinib only slightly reduced EGFR autophosphorylation at 10 μM. As a consequence of the inhibition of the receptor, both our novel compounds affected the phosphorylation of the downstream signaling molecules p-Akt and p-p44/42, whereas gefitinib had a marginal effect on p-Akt at 10 μM. Furthermore, we investigated alterations of core signaling pathways after exposure to UPR1282, in comparison with gefitinib and canertinib, using a recently established highthroughput kinase array [27] . In cell lysates, kinase activity profiling was performed in the absence and presence of 25 μM gefitinib, canertinib, or UPR1282. Data of V ini in treated cells were compared to the DMSO-treated ones and a total of 28, 43, and 21 kinases, linked to many peptide substrates, were identified with a percentage of inhibition of more than 66.6%, caused by gefitinib, canertinib, and UPR1282, including nine common targets (Table 2) . Importantly, EGFR, ErbB2, and ErbB4 inhibition was observed as a consequence of each treatment.
EMT and Inhibition of Cellular Migration
Accumulating evidence suggests a critical role of EMT in epithelial cancer progression, invasion, and metastasis. Cell features, including cell-cell and cell-matrix interactions, are highly affected by EMT, and loss of intracellular cohesion, together with the disruption of extracellular matrix (ECM) and modifications of the cytoskeleton, has been related to increased cell motility and invasiveness [31] . The family of cadherins comprises molecules that are involved in cell-cell adhesion, and their deregulation may result in EMT and cell motility. Recent studies demonstrated the correlations between cell-cell contact and cytoplasmic signaling pathway activation or inhibition [32] . Wnt signaling has emerged as critical pathway in lung tumorigenesis through the β-catenin-mediated transcription of zinc-finger proteins such as Slug and Snail, in which expression is inversely correlated with E-cadherin transcription [33] . Destruction of E-cadherin by receptor tyrosine kinases and Ras pathway was demonstrated to cause release of β-catenin from disassembled junctions between epithelial cells and promote cell transformation [34] . Thus, E-cadherin was first investigated by reverse transcription (RT)-PCR as molecule related to cellular migration. Whereas gefitinib did not affect the level of E-cadherin mRNA in H1975 cells, the exposure to the novel irreversible inhibitors significantly increased its gene expression when compared to DMSO-treated cells ( Figure 3A) . Furthermore, to explore whether UPR1282 and UPR1268 affect cell migration, a scratch motility assay was performed in H1975 cells. Both molecules significantly reduced cell migration in comparison to the control, whereas gefitinib did not result in any effect ( Figure 3 , B and C).
Volume Reduction of H1975-Derived Tumor Spheres
Results from earlier studies illustrated that the sensitivity of twodimensional monolayer cell cultures to anticancer drugs is different from that obtained in three-dimensional culture models [35] . Furthermore, the cancer stem cell (CSC) theory prompted to the reexamination of established views of tumor initiation, progression, and therapeutic resistance [36] . Recently, the use of serum-free medium has been reported to select cell populations harboring CSC-like characteristics, including self-renewal and differentiation into heterogeneous lineages of cancer cells [37] . This experimental approach represents the best strategy so far to obtain the expansion of the tumorigenic cell subpopulation. Furthermore, recent studies unraveled the importance of CSC CD133-positive cells in tumorigenicity and chemoresistance of lung cancer [38] . Thus, to determine whether three-dimensional systems, enriched with CSC-like properties, could be affected by our compounds, we developed tumor spheres from H1975 cells that, after Table 2 . Kinase Activity Profiles of Gefitinib, Canertinib, and UPR1282 in H1975 Cells.
Gef, gefitinib; Can, canertinib; UPR, UPR1282; X, percentage of kinase inhibition of more than 66.6% in comparison with untreated H1975 cells. The acronyms refer to peptides/proteins from http://www.expasy.org/uniprot/.
20 to 25 days of culture, reached a size of approximately 400 to 500 μm in diameter ( Figure 4A ). We evaluated then by RT-PCR the level of CD133 mRNA as marker of stemness, comparing adherent cells versus tumor spheres. In agreement with previous studies, a significantly higher expression of CD133 mRNA was observed in tumor spheres when compared to adherent cells ( Figure 4B ). When treated with gefitinib or the novel TKIs, the total number of H1975 spheroids was not affected. However, the treatment with the novel inhibitors significantly reduced tumor sphere volume when compared to the time zero of treatment ( Figure 4, C and D) . In contrast, gefitinib treatment did not affect the growth of these three-dimensional spheroidal systems (data not shown). Furthermore, the exposure of tumor spheres to UPR1282 and UPR1268 significantly reduced CD133 gene expression ( Figure 4E ), whereas the treatment with gefitinib did not cause any change in CD133 mRNA when compared to DMSO-only-treated spheroids (data not shown).
Tumor Shrinkage in H1975 Xenograft Model and Signaling Pathway Inhibition in Tumor Tissue
To evaluate the potential of our compounds in vivo, we tested the effects of UPR1282 in comparison with gefitinib and canertinib (H1975 IC 50 = 2.4 μM) in H1975-derived xenografts. When tumors were well established and reached an average volume of 150 to 200 mm 3 , the mice were randomized into four treatment groups receiving gefitinib, canertinib, UPR1282, or vehicle. The treatment with either canertinib or UPR1282 caused tumor shrinkage, whereas gefitinib did not affect tumor growth in comparison to the control group ( Figure 5A ). Of note, canertinib significantly inhibited tumor growth after 21 days of treatment. However, this shrinkage was accompanied by a significant reduction of animal body weight compared to untreated animals as well as to mice treated with UPR1282 ( Figure 5B ). Immunohistochemistry was then performed on three tumor tissues per group and EGFR was evaluated as marker to confirm the origin of the tumor from our human lung cancer cells ( Figure 5C ). To evaluate the activity of our novel drug in tumor tissues, we performed an additional kinase activity profiling in tissue lysates, in the absence or presence of 25 μM UPR1282. Data of V ini in treated lysates from H1975 xenograft specimens, which according to hematoxylin-eosin staining in Figure 5C contained more than 80% of tumor cells, were compared to data obtained from the treatment of H1975 cell lysate. This array identified a strong percentage of inhibition (i.e., more than 66.6%) of 17 and 21 kinases in tissue and cell lysates, respectively, including seven common targets ( Figure 5D ). Importantly, EGFR inhibition by UPR1282 was confirmed by the peptide substrate array in both tissue and cells, confirming its powerful activity on this target.
Discussion
The present study demonstrates the activity of novel EGFR irreversible inhibitors against tumor cells, including in vitro and in vivo models of EGFR T790M NSCLC. Moreover, we evaluated several molecular mechanisms underlying the abilities of these novel compounds to effectively antagonize NSCLC aggressive and invasive behavior.
Molecular targeting of EGFR with the first-generation reversible TKIs gefitinib and erlotinib is now an established therapeutic option in advanced NSCLC patients who harbor activating mutations of the receptor [39] . However, the emerging acquired resistance together with the low survival benefit prompts further studies to improve this therapeutic approach. The necessity to overcome the resistance due to the T790M secondary mutation of EGFR led to the development of several second-generation irreversible TKIs of this target [3] . We recently synthesized a series of novel 3-aminopropanamide compounds that demonstrated to be active against H1975 NSCLC cells harboring the EGFR T790M mutation by irreversible binding to the receptor following intracellular activation to a cysteine-trapping chemical species [22] . The present study demonstrates that the two most promising compounds inhibit cell proliferation and induce apoptosis in different NSCLC cell lines at significantly lower concentration than gefitinib. Because the EGFR TKI erlotinib has been approved for the treatment of advanced PDAC in combination with gemcitabine [30] , we also evaluated the new molecules in PANC-1 and MIA PaCa-2 cells. In these cell lines, both our compounds were as active as gefitinib or even more active than the first-generation EGFR TKI. However, the very slight increase in survival obtained with the use of erlotinib [40] and the recent success of multicombinatorial approaches with conventional cytotoxic drugs reduce the impact of EGFR TKIs in the treatment of PDAC [41] .
As expected on the basis of their anti-EGFR activity, the main downstream mediators of the EGFR signal transduction pathways (p-Akt and p-p44/42) were also affected by our novel compounds. However, despite EGFR inhibition was already detectable by Western blot in the nanomolar range of concentrations, the downstream signaling molecules were slightly inhibited at 1 μM, particularly by UPR1268, and more clearly at the highest used concentration (10 μM) for both the inhibitors. Furthermore, using a commercially available 144-peptide array, we detected other tyrosine kinases affected by UPR1282. The restricted subset of the peptides spotted on the array, together with the limited specificity and the use of lysates that cannot reproduce subcellular compartmentalization and protein docking or scaffolding, represent the main interdiction of this study [42] . However, several additional tyrosine kinases that were significantly inhibited by UPR1282, including the fibroblast growth factor receptor 3, whose up-regulation has been correlated to radioresistance in squamous cell carcinoma, were identified [43] . Of note, EphB4 and the focal adhesion kinase 1 (FAK1), which are both involved in the neoplastic transformation process, were also inhibited by UPR1282 in H1975 cells [44, 45] . Additionally, the treatment of the cell lysates with UPR1282 also inhibited c-Met, in which amplification represents the second cause of acquired resistance to the treatment with EGFR TKIs. In particular, the activity of the receptor was reduced by around 53% by UPR1282. Importantly, many kinases, including the previously mentioned, had relevant (although not always below the 66.6% threshold) levels of inhibition in both H1975 cell line and xenografts exposed to UPR1282.
These results potentially extend the use of UPR1282 to the treatment of NSCLCs that harbor mechanisms of resistance different than the EGFR T790M mutation.
The invasive and metastatic capacity of tumor cells constitute two pivotal mechanisms of malignant tumor development. The poor prognosis of lung cancer is related to strong metastasis potential, which is directly correlated with EMT [33] . The transformation of epithelial cells to motile, invasive, and migratory mesenchymal cells is the major feature of such process. Cell adhesion and detachment are regulated by interactions between cell-cell and cell-ECM that coordinate the invasive mechanism [46] . Several classes of proteins participate to invasive cancer phenotype. Recent studies reported the loss of function of the cadherin adhesion complex, and in particular E-cadherin, as hallmark After loading of the sample mix onto the arrays, incubation (at 30°C) was started for 60 cycles utilizing a PamStation 12 instrument. Repeated fluorescent imaging of each array was performed to monitor fluorescence intensities in real time. Spot intensity was quantified and the resulting time-resolved curves were fit to calculate the initial phosphorylation rate (V ini ) using specific kinetic algorithms and appropriate statistical methods. Kinases that were identified to be inhibited more than 66.6% compared to DMSO-treated lysates of both cells and tissues are plotted in the Venn diagram.
of EMT that leads to increased proliferation, invasiveness, and metastasis [47] . Thus, we investigated whether the exposure to UPR1282 or UPR1268 might affect E-cadherin gene expression. Whereas treatment with gefitinib did not affect the level of mRNA coding for E-cadherin in H1975 cells, a significant increase in its gene expression was observed after exposure to our novel compounds. Furthermore, since recent studies demonstrated that EGF modifies cell-ECM adhesion [48] , we tested whether our compounds might affect migration of EGFR T790M H1975 cells. Differently from what was observed after exposure to gefitinib, the novel 3-aminopropanamide compounds significantly reduced cell migration after few hours of treatment, as detected by the woundhealing assay. Such reduction in cell motility agrees with previous evidence on FAK inhibition and increased E-cadherin gene expression.
Accumulating evidence suggests that specific subpopulations of cancer cells within the bulk of tumors undergo different degree of EMT, and this process has been related with the acquisition of stem cell-like characteristics. Both EMT and stemness are implicated in the pathogenesis and chemoresistance of heterogeneous malignant tumors [21, 49] . Treatment strategies for the elimination of cancer, therefore, need to consider the presence of CSCs. Sphere assay has proven to be an excellent technique to isolate CSCs and several studies demonstrated that the three-dimensional aggregates can contain different cell proliferation and metabolic gradients, such as an outer rim of viable and actively proliferating cells and an inner necrotic region [35] . Thus, after generating tumor spheres that overexpress the stem/initiating cell marker CD133, we explored whether our novel EGFR TKIs affected spheroid growth. Conversely to gefitinib, both the 3-aminopropanamide derivatives significantly reduced tumor sphere dimensions. Furthermore, we demonstrated that the level of CD133 mRNA was reduced after exposure to UPR1282 and UPR1268 [37, 50] .
The evaluation of the activity of UPR1282 was also extended to xenograft models of EGFR T790M NSCLC. The chronic administration of UPR1282 in athymic mice was well tolerated and produced significant inhibition of tumor growth, which might result from inhibition of both EGFR and downstream kinase activities. Of note, whereas tumor shrinkage induced by canertinib treatment was accompanied by significant toxicity, UPR1282 did not induce significant loss of body weight and toxicity even after a prolonged treatment. This might be, at least in part, related to the masking of acrylamide warhead that results in reduced risk of covalent interaction with off-target molecules [22] .
In conclusion, our 3-aminopropanamide irreversible EGFR TKIs seem very promising anticancer agents by attacking different key mechanisms involved in the resistance of NSCLC cells to the first-generation EGFR TKIs gefitinib and erlotinib, including the EMT process. These data should prompt future trials that will give the ultimate proof of the utility of these novel anticancer agents for the treatment of lung cancer. Figure W1 . Cell growth inhibition. Microscopic view of the inhibitory effect of UPR1282 and UPR1268 on H1975 cell proliferation. Images were taken after 0-and 72-hour treatment with 0.1% DMSO or UPR1282 and UPR1268 at their respective IC 50 s.
